The pharmaceutical manufacturer Indivior has stopped marketing Opvee, its controversial overdose-reversal medication, after two years of meager sales, outcry from harm reduction groups, and intense scrutiny from New York State’s top law enforcement official.
On Tuesday, New York Attorney General Letitia James unveiled a settlement with Indivior that she said would result in the company refunding all public dollars used to purchase Opvee in New York and accepting the return of all unused units. In the weeks before the settlement was announced, the company began circulating a letter to stakeholders nationwide stating it had “discontinued promotion” of the medication. This decision highlights the challenges pharmaceutical companies face when navigating regulatory landscapes and public perception, particularly in the sensitive area of addiction treatment. As the industry grapples with the implications of this case, it raises questions about the future of similar products and the balance between innovation and responsibility in the market.
Use the database as your supply chain compass →
